TQB-2930

N/A

Report date: 2026/05/09 16:19:20

Base Information

Drug NameTQB-2930
Drug Alias NameTQB-2930
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursColorectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursColorectal Neoplasms +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A